Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Radiolabeled Prucalopride Succinate
- Registration Number
- NCT01807000
- Lead Sponsor
- Shire
- Brief Summary
Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of \[14C\] Prucalopride Succinate in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly Prucalopride Succinate or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 6
- Males aged between 18 and 50 years, inclusive
- Body mass index (BMI) of ≥18 and ≤30 kg/m2
- No more than 2 bowel movements per day or fewer than 3 bowel movement per week
- Provision of signed and dated, written informed consent prior to any study specific procedures
- Have participated in a [14C]-study within the last 6 months.
- Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).
- Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Radiolabeled Prucalopride Succinate Radiolabeled Prucalopride Succinate -
- Primary Outcome Measures
Name Time Method Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time to Maximum Plasma Concentration (Tmax) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Plasma Half-Life (T1/2) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose The time it takes for the blood plasma concentration of a substance to halve.
Volume of Distribution (Vz/F) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose The distribution of a medication between plasma and the rest of the body.
AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Total Body Clearance (CL/F) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose The rate at which a drug is removed from the body.
Maximum Plasma Concentration (Cmax) of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.
Cmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Tmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Half-Life Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose AUC 0→∞ Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Cmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Tmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Half-Life Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate Over 240 hours post-dose Percent Total Radioactivity Excreted in Urine of Radiolabelled Prucalopride Succinate 240 hours post-dose Percent Total Radioactivity Excreted in Stool of Radiolabelled Prucalopride Succinate Over 240 hours post-dose
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Covance Global Clinical Research Unit Inc.
🇺🇸Madison, Wisconsin, United States